Best helicobacter pylori eradication strategy in the era of antibiotic resistance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Su Young | - |
dc.contributor.author | Chung, Jun-Won | - |
dc.date.available | 2020-09-14T00:35:28Z | - |
dc.date.created | 2020-08-10 | - |
dc.date.issued | 2020-08 | - |
dc.identifier.issn | 2079-6382 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/78193 | - |
dc.description.abstract | Antibiotic resistance is the major reason for Helicobacter pylori treatment failure, and the increasing frequency of antibiotic resistance is a challenge for clinicians. Resistance to clarithromycin and metronidazole is a particular problem. The standard triple therapy (proton pump inhibitor, amoxicillin, and clarithromycin) is no longer appropriate as the first-line treatment in most areas. Recent guidelines for the treatment of H. pylori infection recommend a quadruple regimen (bismuth or non-bismuth) as the first-line therapy. This treatment strategy is effective for areas with high resistance to clarithromycin or metronidazole, but the resistance rate inevitably increases as a result of prolonged therapy with multiple antibiotics. Novel potassium-competitive acid blocker-based therapy may be effective, but the data are limited. Tailored therapy based on antimicrobial susceptibility test results is ideal. This review discussed the current important regimens for H. pylori treatment and the optimum H. pylori eradication strategy. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | MDPI | - |
dc.relation.isPartOf | ANTIBIOTICS-BASEL | - |
dc.title | Best helicobacter pylori eradication strategy in the era of antibiotic resistance | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000564069400001 | - |
dc.identifier.doi | 10.3390/antibiotics9080436 | - |
dc.identifier.bibliographicCitation | ANTIBIOTICS-BASEL, v.9, no.8, pp.1 - 16 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85088554897 | - |
dc.citation.endPage | 16 | - |
dc.citation.startPage | 1 | - |
dc.citation.title | ANTIBIOTICS-BASEL | - |
dc.citation.volume | 9 | - |
dc.citation.number | 8 | - |
dc.contributor.affiliatedAuthor | Chung, Jun-Won | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Antibiotic resistance | - |
dc.subject.keywordAuthor | Eradication | - |
dc.subject.keywordAuthor | Helicobacter pylori | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.